-
公开(公告)号：KR1020140069908A
公开(公告)日：2014-06-10
申请号：KR1020120137769
申请日：2012-11-30
Applicant: (주)아모레퍼시픽
IPC: A61K36/258 , A61P27/02
CPC classification number: A61K36/258 , A23L33/105 , A23V2002/00 , A23V2200/30 , A23V2250/2124 , Y10S514/912
Abstract: The present invention relates to a composition comprising a ginseng fruit extract as an active ingredient which provides overall health benefits of the eye by alleviating symptoms of eye fatigue, tightness, dryness, pain, and itching. The composition according to the present invention has an excellent effect of promoting eye health and can effectively alleviating fatigue of the eyes by comprising the extract of ginseng fruit.
Abstract translation: 本发明涉及包含人参果实提取物作为活性成分的组合物，其通过减轻眼睛疲劳，紧张，干燥，疼痛和瘙痒的症状来提供眼睛的整体健康益处。 根据本发明的组合物具有促进眼睛健康的优异效果，并且可以通过包含人参水果的提取物来有效地减轻眼睛的疲劳。
-
公开(公告)号：KR101372037B1
公开(公告)日：2014-03-10
申请号：KR1020100031473
申请日：2010-04-06
Applicant: (주)아모레퍼시픽
IPC: A61K31/425 , A61K31/166 , A61P21/00
CPC classification number: A61K36/481 , A61K31/202 , A61K36/00 , A61K36/185 , A61K36/282 , A61K36/355 , A61K36/424 , A61K36/44 , A61K36/488 , A61K36/537 , A61K36/54 , A61K36/67 , A61K36/70 , A61K36/73 , A61K36/752 , A61K36/815 , A61K36/882 , A61K36/9064 , A61K45/06 , A61K2300/00
Abstract: 본 발명은 PPAR-δ 활성 촉진 물질, AMPK 활성 촉진 물질 및 PGC1-α 활성 촉진 물질을 유효 성분으로 포함하는 근육 타입 변화 촉진, 근육량 증가, 근육 강화, 운동 능력 향상, 지질 감소, 지질 축적 억제, 혈당 감소, 체중 조절 또는 체중 감소용 조성물을 제공한다.
-
公开(公告)号：KR1020130141420A
公开(公告)日：2013-12-26
申请号：KR1020130155424
申请日：2013-12-13
Applicant: (주)아모레퍼시픽
IPC: A61K36/258 , A61P9/00 , A61P29/00
Abstract: The present invention relates to a composition for promoting blood circulation including the ginseng fruit extract as an active ingredient, a composition for blood vessel anti-aging, a blood vessel inflammation therapeutic composition, an angiogenesis promoting composition, a composition for treating ischemic heart diseases,a composition for relieving and treating partial blood flow shortage, in particular, and to a composition which includes ginseng fruit extract as an active ingredient to promote the generation of NO, the survival of blood vessel endothelial cell, and to accelerate the vascularization of blood vessel through the portability increment of the blood vessel endothelial cell and blood vessel tube production. [Reference numerals] (AA) Untreated group;(BB) Comparative example 1 100ug/ml;(CC) Example 1 100ug/ml;(DD) Example 2 100ug/ml;(EE) Untreated group;(FF) Untreated group contrast intensity (compared to untreated group %);(GG) Comparative example 1;(HH) Example 1;(II) Example 2
Abstract translation: 本发明涉及一种用于促进血液循环的组合物，包括人参果实提取物作为活性成分，用于血管抗衰老的组合物，血管炎症治疗组合物，促血管生成组合物，用于治疗缺血性心脏病的组合物， 特别是用于缓解和治疗部分血流短缺的组合物，以及包含人参水果提取物作为活性成分的组合物，以促进NO的产生，血管内皮细胞的存活和加速血管的血管化 通过血管内皮细胞和血管管生产的可移植性增加。 （AA）未处理组;（BB）比较例1 100ug / ml;（CC）实施例1 100ug / ml;（DD）实施例2100μg/ ml;（EE）未处理组;（FF） 强度（与未处理组％相比）;（GG）比较例1;（HH）实施例1;（II）实施例2
-
-
公开(公告)号：KR1020130114877A
公开(公告)日：2013-10-21
申请号：KR1020120037273
申请日：2012-04-10
Applicant: (주)아모레퍼시픽
IPC: C07D493/04 , A61K31/34 , A61P35/00
CPC classification number: C07D493/04
Abstract: PURPOSE: A method for manufacturing a furofuran lignan compound is provided to selectively manufacture (+)-furofuran lignan and (-)-furofuran lignan, which is an optical isomer thereof. CONSTITUTION: A method for manufacturing a furofuran lignan compound comprises the step of O-alkylating one selected from a compound in Chemical Formula 1 and an optical isomer thereof. The furofuran lignan compound comprises a compound in Chemical Formula 7 or 8. The optical isomer of the compound in Chemical Formula 1 is manufactured by a reaction of a compound in Chemical Formula 11 and (+)-diisopropyltryptamine (DIPT) or (-)-DIPT.
Abstract translation: 目的：提供呋喃呋喃木酚素化合物的制备方法，以选择性地制备（+） - 呋喃呋喃木酚素和（ - ） - 呋喃呋喃木酚素，其为其光学异构体。 构成：制备呋喃呋喃木酚素化合物的方法包括将选自化学式1中的化合物和其旋光异构体中的一种O-烷基化的步骤。 呋喃呋喃木酚素化合物包含化学式7或8中的化合物。化学式1中化合物的光学异构体是通过化学式11中的化合物和（+） - 二异丙基色胺（DIPT）或（ - ） - DIPT。
-
Patent Agency Ranking
公开(公告)号：KR1020130078387A
公开(公告)日：2013-07-10
申请号：KR1020110147304
申请日：2011-12-30
Applicant: (주)아모레퍼시픽
CPC classification number: A61K36/82
Abstract: PURPOSE: A composition containing a Camellia sinensis leaf extract, a Camellia sinensis flower extract, and a Camellia sinensis seed extract as active ingredients is provided to activate AMP-activated protein kinase (AMPK), to suppress fatty acid synthesis, and to promote fatty acid oxidation and glucose absorption, thereby preventing and treating metabolic syndrome. CONSTITUTION: A composition for preventing or treating metabolic syndrome contains a Camellia sinensis leaf extract, a Camellia sinensis flower extract, and a Camellia sinensis seed extract as active ingredients, in a weight ratio of 4-12:0.3-4:0.3-4. The composition contains the Camellia sinensis leaf extract and the Camellia sinensis flower and seed extracts in a weight ratio of 4-12:0.2-8. The metabolic syndrome is a glucoside metabolic syndrome or a lipid metabolic syndrome. The metabolic syndrome includes one or more among obesity, hyperlipidemia, type 2 diabetes, arteriosclerosis, myocardial infarction, and angina pectoris. The composition is a pharmaceutical composition. [Reference numerals] (AA) Mixture of Camellia sinensis leaf, flower, and seed extracts; (BB) Camellia sinensis flower extract; (CC) Camellia sinensis seed extract; (DD) Camellia sinensis leaf extract
Abstract translation: 目的：提供含有山茶叶提取物，山茶花提取物和山茶种子提取物作为活性成分的组合物，以激活AMP活化蛋白激酶（AMPK），抑制脂肪酸合成，促进脂肪酸 氧化和葡萄糖吸收，从而预防和治疗代谢综合征。 构成：用于预防或治疗代谢综合征的组合物含有山茶花提取物，山茶花提取物和山茶种子提取物作为活性成分，重量比为4-12:0.3-4:0.3-4。 该组合物含有山茶叶提取物和山茶花和种子提取物，重量比为4-12：0.2-8。 代谢综合征是葡萄糖苷代谢综合征或脂代谢综合征。 代谢综合征包括肥胖，高脂血症，2型糖尿病，动脉硬化，心肌梗塞和心绞痛中的一种或多种。 组合物是药物组合物。 （参考号）（AA）山茶叶，花和种子提取物的混合物; （BB）山茶花提取物; （CC）山茶籽提取物; （DD）山茶叶提取物
-
公开(公告)号：KR1020130047932A
公开(公告)日：2013-05-09
申请号：KR1020110112764
申请日：2011-11-01
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: A composition containing syringaresinol for suppressing aging is provided to enhance SIRT1 expression, to suppress MMP-9 expression and collagen decomposition, and to improve anti-wrinkling. CONSTITUTION: A composition for anti-aging contains 1-80wt% of syringaresinol as an active ingredient. Syringaresinol is contains in one or more extracts selected from a lindseed extract, a Phellodendri cortex extract, an Acanthopanacis cortex extract, a sesame extract, and a ginseng fruit extract. Syringaresinol is prepared using one or more selected from the group consisting of water, an organic solvent, and a mixture thereof. The composition promotes SIRT1(sirtuin 1) expression.
Abstract translation: 目的：提供含有用于抑制老化的丁香精醇的组合物，以增强SIRT1表达，抑制MMP-9的表达和胶原分解，并改善抗皱纹。 构成：抗老化组合物含有1-80重量％的作为活性成分的丁香麻醇。 吩噻嗪醇含有一种或多种提取物，其选自泻药提取物，黄柏提取物，刺五加皮质提取物，芝麻提取物和人参果实提取物。 使用一种或多种选自水，有机溶剂及其混合物的组合制备吸入辛胺醇。 该组合物促进SIRT1（sirtuin 1）表达。
-
公开(公告)号：KR1020130047792A
公开(公告)日：2013-05-09
申请号：KR1020110110484
申请日：2011-10-27
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: A composition containing syringaresinol as an active ingredient is provided to suppress melanogenesis and tyrosinase activity, and to ensure anti-oxidation and skin whitening. CONSTITUTION: A composition for skin whitening contains 0.001-20wt% of syringaresinol as an active ingredient. The composition enhances the brightness and uniformity of skin color. The composition treats hyperpigmentation. The hyperpigmentation includes melasma, seborrheic keratosis, freckle, nevus, and dark circle. Syringaresinol is contained in an extract selected among a lindseed extract, a Phellodendri cortex extract, an Acanthopanacis cortex extract, a sesame extract, and a ginseng fruit extract. The composition is used for removing dead skin cells and promotes dead skin cell turn over. [Reference numerals] (AA) Syringaresinol
Abstract translation: 目的：提供含有作为活性成分的丁香红醇的组合物，以抑制黑素生成和酪氨酸酶活性，并确保抗氧化和皮肤美白。 构成：用于皮肤美白的组合物含有0.001-20重量％的作为活性成分的丁二腈。 该组合物增强了肤色的亮度和均匀性。 该组合物治疗色素沉着过度。 色素沉着过多包括黑斑病，脂溢性角化病，雀斑，痣和黑眼圈。 戒毒素包含在选自泻药提取物，黄柏提取物，刺五加皮质提取物，芝麻提取物和人参果实提取物中的提取物中。 该组合物用于去除死皮细胞并促进死皮细胞翻转。 （标号）（AA）异丙肾上腺素
-
公开(公告)号：KR1020130046115A
公开(公告)日：2013-05-07
申请号：KR1020110110486
申请日：2011-10-27
Applicant: (주)아모레퍼시픽
CPC classification number: A61K31/34 , A23L33/105 , A23V2002/00 , A61K9/0014 , A61K9/0053 , A61K9/0095 , A61K9/1652 , A61K9/2059 , A61K36/00 , A61K36/185 , A61K36/254 , A61K36/258 , A61K36/55 , A61K36/756 , A23V2200/302 , A23V2200/326 , A23V2250/21
Abstract: PURPOSE: A composition containing syringaresinol for suppressing aging of blood vessels is provided to enhance SIRT 1 expression in vascular cells, to activate telomerase, and to suppress aging of blood vessel. CONSTITUTION: A composition for suppressing aging of blood vessel contains syringaresinol as an active ingredient. The composition is used for preventing or treating cardiovascular diseases such as cerebral infarction, cerebral hemorrhage, ischemic heart disease, myocardial infarction, and arteriosclerosis. Syringaresinol is contained in extracts selected among a linseed extract, a Phellodendri cortex extract, an Acanthopanax sessiliflorum extract, a sesame extract, and a ginseng fruit extract. [Reference numerals] (AA) Syringaresinol
Abstract translation: 目的：提供一种含有抑制血管老化的丁香ares酚的组合物，以增强血管细胞中SIRT 1的表达，激活端粒酶，抑制血管老化。 构成：用于抑制血管衰老的组合物含有作为活性成分的丁香腈。 该组合物用于预防或治疗心脑血管疾病如脑梗塞，脑出血，缺血性心脏病，心肌梗死和动脉硬化。 提取物中含有亚麻子提取物，黄柏提取物，刺五加提取物，芝麻提取物和人参果实提取物中的提取物。 （标号）（AA）异丙肾上腺素
-
公开(公告)号：KR1020130045631A
公开(公告)日：2013-05-06
申请号：KR1020110109961
申请日：2011-10-26
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: A composition containing syringaresinol for treating immune diseases is provided to promote SIRT 1 expression in immunocytes and differentiation to type 2 immunocytes, and to prevent or treat immune diseases. CONSTITUTION: A composition for preventing or treating immune diseases contains 1-80 wt% of syringaresinol as an active ingredient. The immune diseases include one or more among allergy, atopic dermatitis, hay fever, and rheumatoid arthritis. Syringaresinol is contained in one or more extracts selected among a linseed extract, a Phellodendri cortex extract, a sesame extract, and a ginseng fruit extract. [Reference numerals] (AA) MRNA of SIRT1 compared to a control group; (BB) 20uM syringaresinol; (CC) 50uM syringaresinol; (DD) 100uM syringaresinol
Abstract translation: 目的：提供一种含有用于治疗免疫疾病的丁香麻醇的组合物，用于促进免疫细胞中的SIRT1表达，分化为2型免疫细胞，并预防或治疗免疫疾病。 构成：用于预防或治疗免疫疾病的组合物含有1-80重量％的作为活性成分的丁香麻醇。 免疫疾病包括过敏，特应性皮炎，花粉症和类风湿性关节炎中的一种或多种。 苯丁酸钠含有选自亚麻子提取物，黄柏提取物，芝麻提取物和人参果实提取物中的一种或多种提取物。 [参考数字] SIRT1与对照组相比的（AA）MRNA; （BB）20uM syringaresinol; （CC）50uM syringaresinol; （DD）100uM syringaresinol
-
-
-
-
-
-
-
-
-
Search Results
274
records
(took 0.028 seconds)
